We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


New screening will protect babies from death and disability

Today the UK National Screening Committee (UK NSC) announced its recommendation to screen every newborn baby in the UK for four new genetic disorders.

This means expanding the current NHS Newborn Blood Spot Screening programme to screen for: Homocystinuria (HCU), Maple Syrup Urine Disease (MSUD), Glutaric Aciduria type 1 (GA1) and Isovaleric Acidaemia (IVA).

Testing for these conditions as part of the current programme, leading to early detection and treatment, will prevent those babies affected from dying or being severely disabled for the rest of their lives.

Dr Anne Mackie, Director of Programmes for the UK NSC, which is supported by Public Health England, said: "We are delighted to announce our recommendation to expand the programme.

"We supported a pilot to look into the impacts of screening for these conditions. Since the start of the pilot in July 2012 more than 700,000 children in England have been tested for these disorders and 47 possible cases identified with 20 confirmed.

"We will help similar numbers each year now the extension is being rolled out."

Andrew Morris from the Manchester Centre for Genomic Medicine said:

"We are delighted that we will be extending newborn screening at Central Manchester Foundation Trust to include 4 new genetic disorders.

Testing for these conditions will lead to early detection and treatment and will prevent affected babies from dying or being severely disabled for the rest of their lives.

The Manchester Centre for Genomic Medicine has already participated in a pilot study of screening for these conditions."

Babies currently have a heel prick blood test at five to eight days old to test for five conditions where early detection and treatment will improve the long-term outcome for the child: phenylketonuria (PKU), congenital hypothyroidism (CHT), sickle cell disease (SCD), cystic fibrosis (CF) and medium-chain acyl-CoA dehydrogenase deficiency (MCADD).

The pilot programme was run by Sheffield Children's NHS Foundation Trust in which over 700,000 babies across the country were screened for the new diseases in addition to the current five for which every newborn is currently screened. Following the results of this, the UK NSC was able to recommend extending the programme to screen for them.

Professor Jim Bonham, national lead for the pilot project and director for newborn screening at Sheffield Children's NHS Foundation Trust, said: "This is fantastic news and everyone who has been involved in the pilot should be really proud of the part they have played in this development."